Discovery of Quinoxaline-Based P1–P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants-Reference-Cited by-同舟云学术

Discovery of Quinoxaline-Based P1–P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

Published:2021-08-18 Issue:16 Volume:64 Page:11972-11989
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Nageswara Rao Desaboini¹,Zephyr Jacqueto¹,Henes Mina¹,Chan Elise T.¹,Matthew Ashley N.¹,Hedger Adam K.¹^ORCID,Conway Hasahn L.²³,Saeed Mohsan²³,Newton Alicia⁴,Petropoulos Christos J.⁴,Huang Wei⁴,Kurt Yilmaz Nese¹^ORCID,Schiffer Celia A.¹^ORCID,Ali Akbar¹^ORCID

Affiliation:

1. Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States

2. Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, United States

3. National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, Massachusetts 02118, United States

4. Monogram Biosciences, South San Francisco, California 94080, United States

Funder

National Institute of Allergy and Infectious Diseases

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00554

Reference54 articles.

1. World Health Organization (WHO). Hepatitis C; Fact Sheet World Health Organization, 2020 (Updated July 2020). https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. (February 25, 2021).

2. Global distribution and prevalence of hepatitis C virus genotypes

3. Global epidemiology and genotype distribution of the hepatitis C virus infection

4. EASL recommendations on treatment of hepatitis C: Final update of the series☆

5. AASLD/IDSA HCV Guidance Panel; Chung, R. T.; Davis, G. L.; Jensen, D. M.; Masur, H.; Saag, M. S.; Thomas, D. L.; Aronsohn, A. I.; Charlton, M. R.; Feld, J. J.; Fontana, R. J. Hepatitis C Guidance: AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C; American Association for the Study of Liver Diseases, 2021 . (February 25, 2021).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?;Journal of Medicinal Chemistry;2024-01-05

2. Identification of Potential Bioactive Compounds from Aspergillus terreus against HCV NS3 Serine Protease;Chemistry & Biodiversity;2023-07-17

3. Meet the Editorial Board Member;Current Medicinal Chemistry;2023-06

4. Synthesis, molecular docking and dynamics studies of pyridazino[4,5-b]quinoxalin-1(2H)-ones as targeting main protease of COVID-19;Journal of Biomolecular Structure and Dynamics;2023-03-23

5. Medicinal chemistry insights into antiviral peptidomimetics;Drug Discovery Today;2023-03